Tirzepatide Results: What Studies Measured and When
What published studies measured for Tirzepatide, when those outcomes were measured, and what is still unproven.
What studies measured
Each outcome below comes from a published study, with its type and size, strongest design first. Animal and cell results are labelled as such and are not human results.
| Outcome | Result | Study type | Source |
|---|---|---|---|
| Joint response plus weight loss | The combined joint-response and weight-reduction end point was met by 31.7% on ixekizumab plus tirzepatide vs 0.8% on ixekizumab alone. | Human RCTn = 271 | Arthritis & rheumatology 2026, PMID 41903163 |
| ACR50 response | ACR50 response was 33.5% with ixekizumab plus tirzepatide vs 20.4% with ixekizumab alone. | Human RCTn = 271 | Arthritis & rheumatology 2026, PMID 41903163 |
| Depressive symptoms (PHQ-9) | Fewer tirzepatide participants shifted to a more severe depressive-symptom category (18.2% vs 24.3% with placebo). | Human RCTn = 4056 | Obesity 2026, PMID 41537305 |
| Suicidal ideation | Suicidal ideation was reported by 0.6% of participants in each group. | Human RCTn = 4056 | Obesity 2026, PMID 41537305 |
| Weight change vs semaglutide | Tirzepatide reduced weight by 20.2% versus 13.7% with semaglutide at week 72. | Human controlled trialn = 751 | The New England journal of medicine 2025, PMID 40353578 |
| Waist circumference | Waist circumference fell by 18.4 cm with tirzepatide versus 13.0 cm with semaglutide. | Human controlled trialn = 751 | The New England journal of medicine 2025, PMID 40353578 |
| Cardiovascular death, MI or stroke | Primary events occurred in 12.2% (tirzepatide) vs 13.1% (dulaglutide); hazard ratio 0.92 (95.3% CI 0.83 to 1.01), noninferior but superiority not shown (P = 0.09). | Human RCTn = 13165 | The New England journal of medicine 2025, PMID 41406444 |
| Cardiovascular death or worsening heart failure | The composite occurred in 9.9% on tirzepatide vs 15.3% on placebo (hazard ratio 0.62, 95% CI 0.41 to 0.95). | Human RCTn = 731 | The New England journal of medicine 2025, PMID 39555826 |
| Quality of life (KCCQ-CSS) | The symptom score improved by 19.5 with tirzepatide vs 12.7 with placebo, a difference of 6.9 (95% CI 3.3 to 10.6). | Human RCTn = 731 | The New England journal of medicine 2025, PMID 39555826 |
| Fat mass and lean mass | At week 72, body weight, fat mass and lean mass changed by -21.3%, -33.9% and -10.9% with tirzepatide vs -5.3%, -8.2% and -2.6% with placebo. | Human RCTn = 160 | Diabetes, obesity & metabolism 2025, PMID 39996356 |
| Share of weight lost as fat | About 75% of weight lost was fat mass and 25% lean mass, for both tirzepatide and placebo. | Human RCTn = 160 | Diabetes, obesity & metabolism 2025, PMID 39996356 |
| Gonadal hormones and sexual function | After 2 months, the tirzepatide group had greater reductions in body weight, waist circumference, binge-eating score and fat mass and a notable increase in lean mass and erectile-function score than the other groups (small pilot). | Human controlled trialn = 83 | Reproductive biology and endocrinology 2025, PMID 40604795 |
| Testosterone and gonadotropins | The tirzepatide group had higher LH, FSH, SHBG, total, free and bioavailable testosterone and lower estradiol than both comparison groups. | Human controlled trialn = 83 | Reproductive biology and endocrinology 2025, PMID 40604795 |
| Weight maintenance after lead-in | From week 36 to week 88, weight changed by -5.5% with continued tirzepatide versus 14.0% (regain) after switching to placebo. | Human RCTn = 670 | JAMA 2024, PMID 38078870 |
| Maintained 80% of weight loss | 89.5% of continuing participants kept at least 80% of lead-in weight loss, versus 16.6% on placebo. | Human RCTn = 670 | JAMA 2024, PMID 38078870 |
| Apnea-hypopnea index, trial 1 (no PAP) | Trial 1: AHI fell by 25.3 events per hour with tirzepatide versus 5.3 with placebo at week 52. | Human RCT | The New England journal of medicine 2024, PMID 38912654 |
| Apnea-hypopnea index, trial 2 (on PAP) | Trial 2: AHI fell by 29.3 events per hour with tirzepatide versus 5.5 with placebo at week 52. | Human RCT | The New England journal of medicine 2024, PMID 38912654 |
| Resolution of MASH without worsening of fibrosis | MASH resolved without worsening fibrosis in 44% (5 mg), 56% (10 mg) and 62% (15 mg) vs 10% with placebo. | Human RCTn = 190 | The New England journal of medicine 2024, PMID 38856224 |
| Blood pressure | By 72 weeks, blood pressure was 6.8 mm Hg systolic and 4.2 mm Hg diastolic lower than with placebo. | Human RCT | Heart 2024, PMID 39084707 |
| Role of weight loss | Weight loss explained 68% of the systolic and 71% of the diastolic blood pressure reduction. | Human RCT | Heart 2024, PMID 39084707 |
| Body weight change | Mean bodyweight change at week 72 was -12·8% (10 mg) and -14·7% (15 mg) versus -3·2% with placebo in people with type 2 diabetes. | Human RCTn = 938 | Lancet 2023, PMID 37385275 |
| Additional weight change after lifestyle intervention | After the lifestyle run-in, tirzepatide produced a further -18.4% weight change versus 2.5% with placebo. | Human RCTn = 579 | Nature medicine 2023, PMID 37840095 |
| Body weight change | Mean weight change at week 72 was -15.0% (5 mg), -19.5% (10 mg) and -20.9% (15 mg) with tirzepatide versus -3.1% with placebo. | Human RCTn = 2539 | The New England journal of medicine 2022, PMID 35658024 |
| Weight reduction of 20% or more | 50% (10 mg) and 57% (15 mg) of participants lost 20% or more of body weight, versus 3% with placebo. | Human RCTn = 2539 | The New England journal of medicine 2022, PMID 35658024 |
| HbA1c change | Glycated hemoglobin fell by 2.40% (10 mg) and 2.34% (15 mg) versus 0.86% with placebo at week 40. | Human RCTn = 475 | JAMA 2022, PMID 35133415 |
| Body weight | Body weight changed by -5.4, -7.5 and -8.8 kg with tirzepatide 5, 10 and 15 mg versus 1.6 kg with placebo. | Human RCTn = 475 | JAMA 2022, PMID 35133415 |
| Liver fat content | Absolute liver fat fell by 8·09% with pooled tirzepatide 10 and 15 mg versus 3·38% with insulin degludec at week 52. | Human RCTn = 296 | The lancet. Diabetes & endocrinology 2022, PMID 35468325 |
| Visceral and abdominal fat | Tirzepatide significantly reduced liver fat content and visceral and abdominal subcutaneous adipose tissue volumes versus insulin degludec. | Human RCTn = 296 | The lancet. Diabetes & endocrinology 2022, PMID 35468325 |
| Triglycerides and metabolites | Triglycerides and diglycerides were lowered significantly versus baseline, dulaglutide and placebo (post hoc analysis). | Human RCTn = 259 | The Journal of clinical endocrinology and metabolism 2022, PMID 34608929 |
| HbA1c change | Mean glycated hemoglobin fell by 1·87% (5 mg), 1·89% (10 mg) and 2·07% (15 mg) versus +0·04% with placebo. | Human RCTn = 478 | Lancet 2021, PMID 34186022 |
Showing the first 30 of 49 rows, strongest sources first.
- No randomized trial was found for tirzepatide in anxiety, ADHD, menopause, rheumatoid arthritis or osteoporosis in PubMed as of 2 October 2026. The only osteoporosis item is an observational cohort association (higher risk), not a trial.
- Psoriatic arthritis (TOGETHER-PsA) is a phase 3b trial of tirzepatide combined with ixekizumab, not tirzepatide alone.
Typical timeline
When the studies above measured their outcomes. This is the study schedule, not a promise of when anyone will notice a change.
| When | What was measured | Study type | Source |
|---|---|---|---|
| Week 72 | Primary weight outcome | Human RCTn = 2539 | The New England journal of medicine 2022, PMID 35658024 |
| Week 40 | Primary endpoint (HbA1c) | Human RCTn = 478 | Lancet 2021, PMID 34186022 |
Before-and-after photos
We don't publish before-and-after photos. They can't be verified, rarely show dose, diet or other drugs, and only the most dramatic results get posted.
Common questions
How long does Tirzepatide take to work?
The studies we summarise measured outcomes at set points, for example Primary weight outcome at Week 72; Primary endpoint (HbA1c) at Week 40. Timelines outside studies vary.
Do you show Tirzepatide before and after photos?
No. Photos can't be verified, rarely show dose, diet or other drugs, and only the most dramatic ones get posted. We summarize measured outcomes instead.
More on Tirzepatide
DosageDoses used in published studies, with the source for each.CalculatorVial, water and dose to syringe units.Side effectsWhat labels and studies report, and what is unknown.PricePrice per mg and per week from dated listings. No vendor links.Legal statusFDA, compounding and WADA status with dates.How to injectSites, syringe types and hygiene, step by step.
Sources
- 1Ixekizumab With Tirzepatide Achieved Greater Disease Control Than Ixekizumab Alone in Adults With Psoriatic Arthritis and Overweight or Obesity: Results From a Randomized Clinical Trial.Arthritis & rheumatology (Hoboken, N.J.) · 2026PMID 41903163Accessed 2 Oct 2026
- 2Psychiatric Safety of Tirzepatide in People With Obesity and No Known Major Psychopathology: A Post Hoc Analysis of SURMOUNT.Obesity (Silver Spring, Md.) · 2026PMID 41537305Accessed 2 Oct 2026
- 3Tirzepatide as Compared with Semaglutide for the Treatment of Obesity.The New England journal of medicine · 2025PMID 40353578Accessed 2 Oct 2026
- 4Cardiovascular Outcomes with Tirzepatide versus Dulaglutide in Type 2 Diabetes.The New England journal of medicine · 2025PMID 41406444Accessed 2 Oct 2026
- 5Tirzepatide for Heart Failure with Preserved Ejection Fraction and Obesity.The New England journal of medicine · 2025PMID 39555826Accessed 2 Oct 2026
- 6Body composition changes during weight reduction with tirzepatide in the SURMOUNT-1 study of adults with obesity or overweight.Diabetes, obesity & metabolism · 2025PMID 39996356Accessed 2 Oct 2026
- 7Short-term impact of tirzepatide on metabolic hypogonadism and body composition in patients with obesity: a controlled pilot study.Reproductive biology and endocrinology : RB&E · 2025PMID 40604795Accessed 2 Oct 2026
- 8Continued Treatment With Tirzepatide for Maintenance of Weight Reduction in Adults With Obesity: The SURMOUNT-4 Randomized Clinical Trial.JAMA · 2024PMID 38078870Accessed 2 Oct 2026
- 9Tirzepatide for the Treatment of Obstructive Sleep Apnea and Obesity.The New England journal of medicine · 2024PMID 38912654Accessed 2 Oct 2026
- 10Tirzepatide for Metabolic Dysfunction-Associated Steatohepatitis with Liver Fibrosis.The New England journal of medicine · 2024PMID 38856224Accessed 2 Oct 2026
- 11Tirzepatide and blood pressure reduction: stratified analyses of the SURMOUNT-1 randomised controlled trial.Heart (British Cardiac Society) · 2024PMID 39084707Accessed 2 Oct 2026
- 12Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2): a double-blind, randomised, multicentre, placebo-controlled, phase 3 trial.Lancet (London, England) · 2023PMID 37385275Accessed 2 Oct 2026
- 13Tirzepatide after intensive lifestyle intervention in adults with overweight or obesity: the SURMOUNT-3 phase 3 trial.Nature medicine · 2023PMID 37840095Accessed 2 Oct 2026
- 14Tirzepatide Once Weekly for the Treatment of Obesity.The New England journal of medicine · 2022PMID 35658024Accessed 2 Oct 2026
- 15Effect of Subcutaneous Tirzepatide vs Placebo Added to Titrated Insulin Glargine on Glycemic Control in Patients With Type 2 Diabetes: The SURPASS-5 Randomized Clinical Trial.JAMA · 2022PMID 35133415Accessed 2 Oct 2026
- 16Effect of tirzepatide versus insulin degludec on liver fat content and abdominal adipose tissue in people with type 2 diabetes (SURPASS-3 MRI): a substudy of the randomised, open-label, parallel-group, phase 3 SURPASS-3 trial.The lancet. Diabetes & endocrinology · 2022PMID 35468325Accessed 2 Oct 2026
- 17Effects of Tirzepatide, a Dual GIP and GLP-1 RA, on Lipid and Metabolite Profiles in Subjects With Type 2 Diabetes.The Journal of clinical endocrinology and metabolism · 2022PMID 34608929Accessed 2 Oct 2026
- 18Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1): a double-blind, randomised, phase 3 trial.Lancet (London, England) · 2021PMID 34186022Accessed 2 Oct 2026
Found an error? Report a correction.